CA2387007A1 - Therapies for tissue damage resulting from ischemia - Google Patents

Therapies for tissue damage resulting from ischemia Download PDF

Info

Publication number
CA2387007A1
CA2387007A1 CA002387007A CA2387007A CA2387007A1 CA 2387007 A1 CA2387007 A1 CA 2387007A1 CA 002387007 A CA002387007 A CA 002387007A CA 2387007 A CA2387007 A CA 2387007A CA 2387007 A1 CA2387007 A1 CA 2387007A1
Authority
CA
Canada
Prior art keywords
pyridazin
benzenesulfonyl
compound
alkyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002387007A
Other languages
English (en)
French (fr)
Inventor
Banavara L. Mylari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CA2387007A1 publication Critical patent/CA2387007A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002387007A 2001-05-24 2002-05-17 Therapies for tissue damage resulting from ischemia Abandoned CA2387007A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29339301P 2001-05-24 2001-05-24
US60/293,393 2001-05-24

Publications (1)

Publication Number Publication Date
CA2387007A1 true CA2387007A1 (en) 2002-11-24

Family

ID=23128899

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002387007A Abandoned CA2387007A1 (en) 2001-05-24 2002-05-17 Therapies for tissue damage resulting from ischemia

Country Status (15)

Country Link
US (1) US6872722B2 (https=)
EP (1) EP1260224B1 (https=)
JP (1) JP2002370984A (https=)
KR (1) KR20020090321A (https=)
CN (1) CN1390547A (https=)
AT (1) ATE289510T1 (https=)
AU (1) AU761191B2 (https=)
CA (1) CA2387007A1 (https=)
CZ (1) CZ20021782A3 (https=)
DE (1) DE60203026T2 (https=)
ES (1) ES2236447T3 (https=)
HU (1) HUP0201738A3 (https=)
PL (1) PL354128A1 (https=)
SK (1) SK7332002A3 (https=)
ZA (1) ZA200203985B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1236720B1 (en) * 2001-02-28 2005-06-15 Pfizer Products Inc. Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
DK1961420T3 (da) * 2005-12-16 2012-08-27 Sanwa Kagaku Kenkyusho Co Middel til forebyggelse og behandling af akut nyresvigt
KR20080108465A (ko) * 2006-02-20 2008-12-15 가부시키가이샤산와카가쿠켄큐쇼 뇌졸중에 있어서의 뇌허혈 또는 뇌허혈 재관류 장해의 예방또는 치료제
WO2022197487A1 (en) 2021-03-18 2022-09-22 Banavara MYLARI Combination of aldose reductase inhibitors and probenecid for the treatment of diabetic complications

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47592B1 (en) 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
JPH01258671A (ja) * 1987-12-01 1989-10-16 Morishita Pharmaceut Co Ltd ５−（１ｈ−イミダゾール−１−イル）−３（２ｈ）−ピリダジノン誘導体
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
WO1992017446A2 (en) * 1991-03-28 1992-10-15 Pfizer Inc. Pyridazinone acetic acids aldose reductase inhibitors
US5834466A (en) 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
US5506228A (en) * 1995-02-23 1996-04-09 Merck & Co., Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US5670504A (en) * 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
CN1142148C (zh) * 1997-11-19 2004-03-17 兴和株式会社 新颖的哒嗪衍生物和含有其作为有效成分的药物
TWI241295B (en) * 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
JP2000247959A (ja) * 1999-02-26 2000-09-12 Kowa Co ピリダジン−３−オン誘導体及びこれを含有する医薬
EP1236720B1 (en) * 2001-02-28 2005-06-15 Pfizer Products Inc. Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
CA2442476A1 (en) * 2001-03-30 2002-10-10 Pfizer Products Inc. Pyridazinone aldose reductase inhibitors

Also Published As

Publication number Publication date
US6872722B2 (en) 2005-03-29
AU761191B2 (en) 2003-05-29
EP1260224B1 (en) 2005-02-23
JP2002370984A (ja) 2002-12-24
DE60203026D1 (de) 2005-03-31
CN1390547A (zh) 2003-01-15
CZ20021782A3 (cs) 2003-03-12
EP1260224A1 (en) 2002-11-27
HUP0201738A2 (hu) 2003-02-28
ES2236447T3 (es) 2005-07-16
HUP0201738A3 (en) 2003-11-28
ATE289510T1 (de) 2005-03-15
US20030008871A1 (en) 2003-01-09
ZA200203985B (en) 2003-11-20
DE60203026T2 (de) 2006-05-04
PL354128A1 (en) 2002-12-02
KR20020090321A (ko) 2002-12-02
SK7332002A3 (en) 2003-05-02
AU4068502A (en) 2002-11-28
HU0201738D0 (https=) 2002-07-29

Similar Documents

Publication Publication Date Title
RU2054004C1 (ru) Производные 3(2н)-пиридазинона или их фармацевтически приемлемые соли и фармацевтическая композиция на их основе
KR20220020410A (ko) 심장 상태에 대한 피리미딘디온 화합물
JPWO1991016314A1 (ja) ピリダジノン誘導体
CA2065364A1 (en) Arylpyridazines, their manufacture, use and medicaments containing them
CA2442476A1 (en) Pyridazinone aldose reductase inhibitors
ES2200968T3 (es) Compuestos de imidazol como inhibidores de fosfodiesterasa vii.
US20210171503A1 (en) Glycolate oxidase inhibitors and use thereof
CA2373395C (en) Sulfonyl pyridazinone compounds useful as aldose reductase inhibitors
ES2214891T3 (es) Benzoilpiridazinas.
AU761191B2 (en) Therapies for tissue damage resulting from ischemia
US20070225308A1 (en) 2-Amino Quinazoline Derivative
EP1265871B1 (en) Pyridazinyl phenyl hydrazones useful against congestive heart failure
ES2237690T3 (es) Derivados sustituidos de alquilaminopiridazinona, procedimiento para la preparacion de los mismos y composicion farmaceutica que los contienen.
AU2002236131B2 (en) Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors
AU2002236131A1 (en) Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors
CN117800955A (zh) 2位或4位吡喃酮类衍生物及其药物组合物、制备方法和用途
JPH06199842A (ja) ピリダジノン誘導体及びその製造方法
CN108863948A (zh) 嘧啶取代的酰肼衍生物及其用途
JPWO1996032370A1 (ja) ４−アミノ−５−オキシ−２，６，６−トリメチル−２−シクロヘプテン化合物

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued